Stella Pharma Corporation
Stock Price Chart
2026/11/20 20:23 UpdatedPrice Trend
2026/11/20 20:23 UpdatedPrice & Trading Details
2026/11/20 20:23 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/11/01Financial Performance
2026/11/22 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥229M | ¥269M | ¥961M | ¥323M |
| Gross Profit | ¥207M | ¥217M | ¥846M | ¥279M |
| Operating Income | -¥807M | -¥760M | -¥90M | -¥749M |
| Pretax Income | -¥773M | -¥759M | -¥134M | -¥771M |
| Net Income | -¥779M | -¥764M | -¥141M | -¥781M |
| EPS | -¥26.97 | -¥24.66 | -¥4.22 | -¥22.95 |
| Operating Margin | -352.20% | -282.12% | -9.39% | -231.60% |
| Balance Sheet | ||||
| Total Assets | ¥4,329M | ¥3,821M | ¥5,417M | ¥4,487M |
| Total Equity | ¥2,753M | ¥2,377M | ¥3,207M | ¥2,427M |
| Total Liabilities | ¥1,577M | ¥1,444M | ¥2,210M | ¥2,060M |
| Cash | ¥2,710M | ¥2,053M | ¥3,206M | ¥2,823M |
| Interest-bearing Debt | ¥1,093M | ¥933M | ¥767M | ¥747M |
| Equity Ratio | 63.58% | 62.22% | 59.21% | 54.08% |
| D/E Ratio | 0.40 | 0.39 | 0.24 | 0.31 |
| Cash Flow | ||||
| Operating CF | -¥828M | -¥877M | ¥140M | -¥335M |
| Investing CF | -¥30M | -¥9M | ¥288M | -¥16M |
| Financing CF | ¥292M | ¥228M | ¥721M | -¥33M |
| Free CF | -¥857M | -¥888M | ¥128M | -¥346M |
| Efficiency | ||||
| ROE | -28.30% | -32.13% | -4.39% | -32.18% |
| ROA | -17.99% | -19.99% | -2.60% | -17.41% |
Latest IR Information
-
2nd Quarter Financial Results Presentation
Interim sales decreased 12.5% year-over-year to 175 million yen. Selling, general and administrative expenses increased mainly due to production transfer-related costs, resulting in an operating loss of -498 million yen, ordinary loss of -467 million yen, and interim net loss...
Read more -
Notification of Partial Revision Approval to the Marketing Authorization for Stevoronin® Intravenous Infusion Bag 9000mg/300mL for BNCT Indicated for Recurrent Meningioma
The BNCT pharmaceutical Stevoronin® Intravenous Infusion Bag 9000mg/300mL, indicated for recurrent meningioma, has received partial revision approval to its marketing authorization. This is the first approval in Japan for an indication targeting recurrent meningioma. The company promotes indication expansion as...
Read more -
Notice of Completion of Payment for the 4th Third-Party Allotment of New Shares and Stock Acquisition Rights under the Share and Stock Acquisition Rights Issuance Program Agreement
Issued 1,000,000 new shares under the 4th third-party allotment at 373 yen per share, raising a total of 373,000,000 yen. Issued 10,500 stock acquisition rights with issuance proceeds of 598,374,000 yen; potential shares total 1,050,000 shares. Allottee: CVI Investments, Inc....
Read more -
Notice Regarding the Regulatory Advisory Panel's Deliberation Results for Stevoronin® for Recurrent Meningioma
A deliberation result was obtained for expanding the indication of the BNCT drug Stevoronin to recurrent meningioma; following the prescribed administrative procedures, the application is expected to proceed to marketing authorization. The application began in March 2026, and the impact...
Read more -
Notice of Issuance of New Shares and Share Acquisition Rights by the Fourth Third-Party Allocation under the Share and Share Acquisition Rights Issuance Program
Through the fourth third-party allocation, Stella Pharma Corporation will issue 1,000,000 ordinary shares at 373 yen each, raising approximately 966 million yen. In addition, 10,500 share acquisition rights will be issued at 288 yen each, creating approximately 1,050,000 potential shares....
Read more
Latest News (5 items)
Company Information
About
Stella Pharma Corporation engages in research and development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma and angiosarcoma, glioblastoma, and thoracic malignant tumor. Stella Pharma Corporation was incorporated in 2007 and is headquartered in Osaka, Japan.